Fractionated stereotactic radiotherapy plus bevacizumab for multiple brain metastases from lung adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, controlled phase III randomized trial that will assign participants 1:1:1 to FSRT plus bevacizumab, FSRT alone, or whole-brain radiotherapy with a simultaneous integrated boost. FSRT is delivered as 30 Gy in five daily 6 Gy fractions, bevacizumab is given IV 7.5 mg/kg every three weeks for four cycles starting one week before FSRT, and WBRT/SIB is delivered as 25 Gy to the brain with a 40 Gy boost in 10 fractions. Eligible patients have lung adenocarcinoma with multiple brain metastases meeting predefined size/number criteria and are judged unsuitable for single-session SRS. The study will measure intracranial control and safety outcomes to determine whether the addition of bevacizumab provides clinical benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old;
* Cellular or histopathological confirmation of lung adenocarcinoma;
* Prior to enrollment, brain enhanced magnetic resonance imaging shows (1) 1-2 brain metastases, with at least one measuring ≥3 cm in diameter; or (2) 3-10 brain metastases, with at least one measuring ≥2 cm in diameter; or (3) 11-20 brain metastases; and deemed unsuitable for single-session SRS by radiation oncologists;
* At the time of enrollment, the extracranial disease status is stable;
* Eastern Cooperative Oncology Group (ECOG) physical fitness status score 0-2 points
* Normal liver, kidney, and bone marrow function within 14 days prior to enrollment: peripheral blood white blood cell count ≥ 4 × 10\^9/L; neutrophil count ≥ 1.5 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, hemoglobin ≥ 100g/L, serum creatinine\<1.5 times the upper limit of normal values; Bilirubin\<1.5 times the upper limit of normal value; Transaminase\<2 times the upper limit of normal value;
* The patient and their family agree and sign an informed consent form.

Exclusion Criteria:

* There are contraindications for bevacizumab, such as a history of cardiac and/or thromboembolic events, or uncontrolled hypertension;
* Meningeal metastasis or extensive intracranial metastasis are not suitable for FSRT;
* Bleeding tendency or coagulation dysfunction;
* Patients with hemoptysis (≥ 1/2 teaspoon of fresh blood per day) within the past month;
* Use full dose anticoagulant therapy within the past month;
* Has experienced severe vascular disease in the past 6 months;
* Have experienced gastrointestinal fistula, perforation, or abdominal abscess within the past 6 months;
* Has experienced hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York Class II or above), acute myocardial infarction, cerebral infarction, cerebral parenchymal hemorrhage, or other active cerebrovascular or cardiovascular diseases within the past 6 months;
* Patients with a history of arterial aneurysm or arteriovenous malformation;
* Having undergone major surgery within 28 days, or minor surgery or needle biopsy within 48 hours;
* Urinary protein 3-4+, or 24-hour urinary protein quantification\>1g;
* Simultaneously accompanied by serious and uncontrolled other diseases.

Where it's running

• Sun yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Hui Liu
• Email: liuhui@sysucc.org.cn
• Phone: 02087343031

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.